Previous 10 | Next 10 |
Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GA Phase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are progressing KZR-261 nominated as the first oncology clinical candidate from the Protein Sec...
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced four pos...
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler...
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this Read more ...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of t...
Kezar Life Sciences (NASDAQ: KZR ): Q2 GAAP EPS of -$0.46 beats by $0.02 . More news on: Kezar Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiated Phase 2 PRESIDIO and MARINA trials have been initiated evaluating KZR-616 in DM, PM, AIHA, and ITP patients Nomination of ...
Kezar Life Sciences (NASDAQ: KZR ) files a $150M shelf offering for a mix of securities. More news on: Kezar Life Sciences, Inc., Healthcare stocks news, Read more ...
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this Read more ...
Thinly traded micro cap Kezar Life Sciences (NASDAQ: KZR ) is up 2% after hours on the heels of positive data from the Phase 1b open-label dose-escalation portion of its Phase 1/2 study of KZR-616 in patients with systemic lupus erythematosus (SLE). The results were presented...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...